Cervical spinal cord atrophy
An early marker of progressive MS onset
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 24, 2017
- Accepted in final form November 28, 2017
- First Published January 22, 2018.
Author Disclosures
- Burcu Zeydan, MD,
- Xinyi Gu, MD,
- Elizabeth J. Atkinson, MS,
- B. Mark Keegan, MD,
- Brian G. Weinshenker, MD,
- Jan-Mendelt Tillema, MD,
- Daniel Pelletier, MD,
- Christina J. Azevedo, MD,
- Christine Lebrun-Frenay, MD,
- Aksel Siva, MD,
- Darin T. Okuda, MD,
- Kejal Kantarci, MD, MS and
- Orhun H. Kantarci, MD
- Burcu Zeydan, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Turkish Neurological Society
NONE
NONE
NONE
NONE
NONE
NONE
- Xinyi Gu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elizabeth J. Atkinson, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Idec Industry -- Lab-based, Re-analyses of champs and champions data, co-investigator, 1/31/2017 - 1/30/2018
NIA P01AG 04875-33, Co-investigator, 6/15/2015-4/30/2020 Physiology of Bone Metabolism in an Aging Population
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- B. Mark Keegan, MD,
NONE
NONE
NONE
(1)Multiple Sclerosis and Related Disorders 2011-present
NONE
Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning Cambridge University Press 2016
NONE
Novartis, Bristol Meyers Squibb, Bionest
NONE
NONE
NONE
Biogen: ARISE study
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brian G. Weinshenker, MD,
(1) Novartis data safety monitoring board member (2) Mitsubishi Pharmaceuticals data safety monitoring board member
NONE
NONE
1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation 3. Neurology, editorial board member, 2014-present; no compensation
1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.,Oxford University,MVZ Labor PD Dr. Volkmann und Kollegen GbR, Hospices Civil de Lyon
NONE
NONE
1. Caladrius: consulting regarding design of neuromyelitis optica clinical trial 2. Brainstorm Therapeutics: consulting regarding design of neuromyelitis optica clinical trial
NONE
(1)MedImmune Pharmaceuticals, Adjudication Committee Member (2)Alexion Pharmaceuticals, Adjudication Committee Member
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation, sponsor of research in NMO, 10/2008-08/2017
NONE
NONE
NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR and Hospices Civil de Lyon
NONE
NONE
NONE
- Jan-Mendelt Tillema, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NCATS/NIH. KL2TR000136-09
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Pelletier, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Pelletier received consulting fees from Biogen, EMD Serono, Sanofi-Genzyme, Novartis, Hoffmann LaRoche, and Actelion.
NONE
NONE
NONE
NONE
NONE
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Christina J. Azevedo, MD,
Advisory boards for Genzyme, Guerbet, Genentech, and Biogen-Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institutional Career Development Award through the University of Southern California Clinical and Translational Science Institute, Grant # UL1TR001855
NONE
Race to Erase MS Foundation Young Investigator Award
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Lebrun-Frenay, MD,
serving on a scientific advisory board from Biogen, Novartis, Merck, Genzyme,Teva, Roche
NONE
Funding for travel or speaker honoraria from Biogen, Merck, Genzyme, Roche
Serving as editorial advisory board member for Revue Neurologique (Paris) Elsevier, Neurology and therapy.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
UT Southwestern, Dallas, TX. Clinical advisor and senior professor.
Franch MS Society (SFSEP) EDMUS (OFSEP Center) Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Aksel Siva, MD,
NONE
NONE
Dr. Siva received travel and registration coverage for attending several national or international congresses or symposia, from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Novartis, Sanofi-Genzyme, Roche and Teva (all unrelated to this work).
Journal of Neurological Sciences (editorial board member / no compensation) Journal of Headache and Pain (editorial board member / no compensation) Turkish Neurological Journal (editorial board member / no compensation)
NONE
NONE
NONE
Dr Siva reports receiving honoraria or consultation fees from the commercial entities of Biogen Idec, Novartis, Merck-Serono, Bayer, Teva, Sanofi-Genzyme and Roche within the last two years (all unrelated to this work).
Giving educational presentations at programmes & symposia prepared by Excemed internationally - nonprofit entity (all unrelated to this work) and honoraria for giving educational presentations at several national or international congresses or symposia and consultation fees from Sanofi- Genzyme, Merck Serono, Biogen Idec / Gen Pharma of Turkey and Teva
NONE
NONE
NONE
Dr. Siva reports receiving research grants to his department from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants numbers : 109S070 and 112S052 - noncommercial entity. / unrelated to the study submitted
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Darin T. Okuda, MD,
NONE
NONE
(1). Acorda Therapeutics, travel and speaker fees (2). Genentech, travel and speaker fees (3). Genzyme, travel and speaker fees (4). Teva, travel and speaker fees
NONE
1. Methods, Apparatuses, and Systems for Creating 3- Dimensional Representations Exhibiting Geometric and Surface Characteristics of Brain Lesions UTSD.P3102US.P1/11606483 (Pending) 2. System and method for medical surveillance through personal communication device US15/356,342 (Pending)
NONE
NONE
(1). Celgene (2). Bayer (3). EMD Serono (4). Genzyme (5). Novartis
(1). Acorda Therapeutics (2). Genzyme (3). TEVA Neuroscience
NONE
NONE
Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kejal Kantarci, MD, MS and
Data safety monitoring board member for Takeda Global Research & Development Center, Inc., Pfizer Inc. and Janssen Alzheimer Immunotherapy
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
R01 AG040042 (PI); 2011-2018, P50AG044170/P2(PI); 2012- 2017;U01 NS100620 (PI); RF1 AG057547 (PI)
NONE
Minnesota Partnership for Biotechnology and Medical Genomics; 2013-2015
NONE
NONE
NONE
NONE
NONE
NONE
- Orhun H. Kantarci, MD
NONE
NONE
1) Istanbul MS Days, Novartis Pharmaceuticals, speaker honoraria payment to Mayo Clinic. No personal compensation. 2) Invited professor program, Biogen- Boston, speaker honoraria payment to Mayo Clinic. No personal compensation
NONE
NONE
NONE
NONE
NONE
NONE
Grant review for The National Multiple Sclerosis Society.
NONE
Already listed in the paper but reported again: Dr. Orhun Kantarci receives research support from Biogen. Dr.Kejal Kantarci serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])
Dr.Kejal Kantarci (wife) serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])
Dr.Kejal Kantarci (wife) serves on the data safety monitoring board of Takeda Global Research and Development Center, Inc, and the data monitoring boards of Pfizer Inc and Janssen Alzheimer Immunotherapy and is funded by the NIH (R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], R01 AG11378[Co-I], U19 AG10483[Co-I] U01 AG042791[Co-I]) and Minnesota Partnership for Biotechnology and Medical Genomics (PO03590201[PI])
2006-2009 Multiple Sclerosis Society for support in multiple sclerosis research unrelated to this publication; 2008-2009 Mayo Foundation CR20 award for support in multiple sclerosis research unrelated to this publication; 2009-2011 Hilton Foundation support in multiple sclerosis research unrelated to this publication
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (B.Z., X.G., B.M.K., B.G.W., J.-M.T., O.H.K.), Department of Radiology (B.Z., K.K.), and Department of Health Sciences Research (E.J.A.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology (X.G.), The affiliated ZhongShan Hospital of DaLian University, LiaoNing, China; Multiple Sclerosis Center (D.P., C.J.A.), Keck School of Medicine, University of Southern California, Los Angeles; Department of Neurology (C.L.-F.), Hopital Pasteur, Nice, France; Cerrahpasa School of Medicine (A.S.), Istanbul University, Turkey; and Department of Neurology & Neurotherapeutics (D.T.O.), Clinical Center for Multiple Sclerosis, University of Texas Southwestern Medical Center, Dallas.
- Correspondence to
Dr. Kantarci kantarci.orhun{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.